Trial Profile
A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Endometrial cancer; Leiomyosarcoma; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- Acronyms HGUS Study
- 05 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 May 2025.
- 25 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.
- 20 Sep 2023 The trial has been completed in Germany, according to an European Clinical Trials Database record.